Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

NMDAR Modulation As a Therapeutic Target and Probe of Neural Dysfunction in OCD

NCT02624596 is registered in ClinicalTrials.gov with Stanford University as lead sponsor.

NCT NCT02624596
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02624596 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
NMDAR Modulation As a Therapeutic Target and Probe of Neural Dysfunction in OCD
Lead sponsor
Stanford University
Phase
Phase 2
Overall status
Completed
Start date
August 16, 2016
Completion date
June 28, 2021
Enrollment
120 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

obsessive-compulsive disorder